Uso de lacosamida oral en un paciente con estado epiléptico parcial refractario

Turpín-Fenoll, L; Millán-Pascual, Jorge; Navarro-Muñoz, Santiago; P, del Saz-Saucedo; Rueda-Medina, I

doi:10.33588/rn.5010.2010281

Cited by 7 publications

(17 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are 19 published articles on the use of IV LCM in SE and acute repetitive seizures, including 10 single case reports (Kellinghaus et al., ; Tilz et al., ; Turpin‐Fenoll et al., ; Chen et al., ; Granda‐Mendez et al., ; Krause et al., ; LaRoche & Shivdat‐Nanhoe, ; Parkerson et al., ; Shiloh‐Malawsky et al., ; Torres‐Cano et al., ; see Table ) and 9 retrospective case series (Albers et al., ; Goodwin et al., ; Höfler et al., ; Kellinghaus et al., ; Koubeissi et al., ; Rantsch et al., ; Cherry et al., ; Jain & Harvey, ; Mnatsakanyan et al., ; see Table ).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Lacosamide as a new treatment option in status epilepticus

2013

View full text Add to dashboard Cite

SUMMARYStatus epilepticus is among the most common neurologic emergencies, with a mortality rate of up to 20%. The most important therapeutic goal is fast, effective, and welltolerated cessation of status epilepticus. Intravenous phenytoin/fosphenytoin, phenobarbital, or valproate is the current standard treatment after failure of benzodiazepines. Lacosamide as a new antiepileptic drug has been available as an intravenous solution since 2009. To date, PubMed lists 19 studies (10 single case reports and 9 case series), reporting a total of 136 episodes of refractory status epilepticus (50% nonconvulsive status epilepticus, 31% focal status epilepticus, and 19% convulsive status epilepticus) treated with lacosamide. The most often used bolus dose was 200-400 mg over 3-5 min. The overall success rate was 56% (76/136). Adverse events (AEs) were reported in 25% (34/136) of patients: mild sedation in 25 cases, 1 patient with possible angioedema, 2 with allergic skin reaction, 4 with hypotension, and 1 with pruritus. One patient developed a third-degree atrioventricular (AV) block and paroxysmal asystole. Overall, the rate of AEs was low. Current evidence on the use of intravenous lacosamide in acute seizures and status epilepticus is restricted to retrospective case reports and case series (class IV). Further prospective studies to inform clinicians are necessary.

show abstract

Section: Methodsmentioning

confidence: 99%

“…Turpin‐Fenoll et al. () presented a 72‐year‐old patient with a nonconvulsive SE (NCSE) 2 weeks after his first tonic–clonic seizure. As PHE had previously caused bradycardia and respiratory failure, it was avoided as first‐line therapy.…”

Section: Methodsmentioning

confidence: 99%

Lacosamide as a new treatment option in status epilepticus

2013

View full text Add to dashboard Cite

show abstract

“…Both LCS and its metabolites are excreted in urine. [3][4][5][6] Three received oral LCM, 4-6 and 1 was treated through a gastrocutaneous fistula. Cardiovascular events have also been reported.…”

Section: Discussionmentioning

confidence: 99%

“…1 Data are lacking regarding simple partial RSE outcomes. [3][4][5][6] We present 2 patients with simple partial RSE, treated with a single oral dose of LCM (300 mg). 1 Currently, no prospective clinical trial on lacosamide (LCM) use in SE, or in RSE, has been completed.…”

mentioning

confidence: 99%

Single-Dose Oral Lacosamide in Refractory Simple Partial Status Epilepticus

Hawkes

Suárez

Ugarnes

et al. 2013

Clinical Neuropharmacology

View full text Add to dashboard Cite

show abstract

“…Vier weitere Fallberichte wurden über Zitate gefunden [7,11,13,37]. Aus der LCM-Pub-med-Recherche und daraus resultierenden Literaturverweisen ergaben sich weitere vier Fallberichte [34,38,40,41] gleichbare Wirksamkeiten von VPA und LEV, wobei sie allerdings Patienten mit NKSE oder bereits intubierte Patienten von ihrer Studie ausnahmen. Zudem wurden Patienten, die sich eine Dauertherapie mit LEV nicht leisten konnten, der VPA-Gruppe zugeführt, sodass vermutlich sozial privilegierte Patienten die LEVBehandlungsgruppe bildeten.…”

Section: Behandlungserfolg In Den Einzelfallberichtenunclassified

Erfahrungen mit Levetiracetam in der Behandlung des Status epilepticus

Rösche¹,

Pohley²,

Rantsch³

et al. 2012

Fortschr Neurol Psychiatr

View full text Add to dashboard Cite

Non-convulsive status epilepticus and epilepsia partialis continua are common epileptic conditions for which straightforward recommendations based on controlled randomised trials for treatment of therapy refractory courses are lacking. Therefore in these conditions sometimes antiepileptic drugs that are not approved by governmental authorities for the treatment of status epilepticus (SE) are used. Here we review all case reports and case series concerning the treatment of SE with levetiracetam (LEV), that had been listed in pub-med up to December 12th 2011. Additionally we analysed abstracts and papers in peer reviewed journals, that were listed in the references of the primarily reviewed papers. Furthermore we looked for LEV treatments in papers on the use of lacosamide (LCM) in SE. LEV was given in dosages ranging from 500 mg to 9000 mg per day. Side effects were especially sedation and irritability. Estimated on the basis of the case series the overall success-rate of LEV in terminating status epilepticus may be set in a range between 53.7% and 58.1%. Therefore LEV may be a useful alternative for the treatment of SE when the approved drugs are contraindicated or when these drugs have been taken without success.

show abstract

Uso de lacosamida oral en un paciente con estado epiléptico parcial refractario

Cited by 7 publications

References 0 publications

Lacosamide as a new treatment option in status epilepticus

Lacosamide as a new treatment option in status epilepticus

Single-Dose Oral Lacosamide in Refractory Simple Partial Status Epilepticus

Erfahrungen mit Levetiracetam in der Behandlung des Status epilepticus

Contact Info

Product

Resources

About